EMAIL THIS PAGE TO A FRIEND

PloS one

Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro.


PMID 26295571

Abstract

The aim of this study was to explore the therapeutic effect of natural killer (NK) cells on human doxorubicin-sensitive and resistant breast adenocarcinoma. Human doxorubicin-sensitive and resistant breast cancer cell lines (MCF-7 and MCF-7/ADR) were tagged with renilla luciferase (Rluc) (MCF-7/RC and MCF-7/ADR/RC). NK cells were tagged with enhanced firefly luciferase (effluc) using a recombinant retrovirus transfection (NKF). Expression of Rluc, effluc, and NK cell surface markers CD16, CD56 as well as death receptors, DR4 and DR5, were assessed by using flow cytometry. In vitro cytotoxic effect of NK to MCF-7 and MCF-7/ADR was measured and in vivo bioluminescence imaging was also performed to visualize MCF-7/RC, MCF-7/ADR, and NKF in an animal model. NK92-MI, MCF-7, and MCF-7/ADR cells were successfully labeled with Rluc or effluc. Both the target breast cancer cells (with Rluc) and therapeutic NK cells (with effluc) were noninvasively visualized in nude mice. Doxorubicin-resistant breast cancer cells (MCF-7/ADR) presented a higher expression of DR5 and were more sensitive to NK cells compared with doxorubicin-sensitive breast cancer cells (MCF-7). The results of present study suggest that NK cell therapy has a therapeutic effect on doxorubicin-sensitive and resistant breast cancer cells.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

M6250
2-Mercaptoethanol, ≥99.0%
C2H6OS
M3148
2-Mercaptoethanol, for molecular biology, for electrophoresis, suitable for cell culture, BioReagent, 99% (GC/titration)
C2H6OS
M7154
2-Mercaptoethanol, for electrophoresis
C2H6OS
63689
2-Mercaptoethanol, BioUltra, for molecular biology, ≥99.0% (GC)
C2H6OS
SAB3500428
Anti-DR4 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
D3938
Anti-DR5 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB3500427
Anti-DR5 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
AV02065
Anti-TNFRSF10A antibody produced in rabbit, IgG fraction of antiserum
HPA054475
Anti-TNFRSF10A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1406725
Anti-TNFRSF10B antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA023625
Anti-TNFRSF10B antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2102489
Anti-TNFRSF10B antibody produced in rabbit, affinity isolated antibody
F7876
Folic acid, ≥97%
C19H19N7O6
F8758
Folic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥97%
C19H19N7O6
F8798
Folic acid, meets USP testing specifications
C19H19N7O6
SAB4700538 Monoclonal Anti-CD262 antibody produced in mouse, clone DR5-01-1, purified immunoglobulin, buffered aqueous solution
WH0008797M1
Monoclonal Anti-TNFRSF10A antibody produced in mouse, clone 2E8, purified immunoglobulin, buffered aqueous solution
SAB1404626
Monoclonal Anti-TNFRSF10A antibody produced in mouse, clone 2E9, purified immunoglobulin, buffered aqueous solution
WH0008795M1
Monoclonal Anti-TNFRSF10B antibody produced in mouse, clone 2D6, purified immunoglobulin, buffered aqueous solution